Should you store your API manufacturing data on the cloud or on your own servers? The answer is both. The India API market research study shows that cloud‑based deployment models hold the largest share (45%), but hybrid models are the fastest‑growing. Why? Because pharma companies are paranoid — and rightfully so. A single data breach could expose trade secrets worth billions. But keeping everything on‑premise is expensive and limits collaboration.

What's the hybrid compromise? Keep critical data (formulas, customer lists) on your own servers, but use the cloud for non‑sensitive analytics, supply chain tracking, and collaboration with partners. The India API market trends highlight that composite APIs (which combine multiple data sources into a single call) are emerging as a flexible solution for hybrid environments. They allow developers to pull data from both on‑premise databases and cloud services without writing complex code.

But hybrid isn't simple. It requires skilled IT staff to manage both environments and ensure they talk to each other securely. That's why many small manufacturers stick with all‑cloud or all‑on‑premise. But as cloud security improves and costs drop, hybrid is becoming more accessible.

The bottom line: there's no one‑size‑fits‑all. Assess your risk tolerance, budget, and IT capabilities. For most mid‑sized pharma companies, hybrid is the smartest path forward — you get the benefits of the cloud without the nightmares of a breach.